anti-CD19 CAR T cells (Shenzhen Second People's Hospital)

This autologous chimeric antigen receptor (CAR) T-cell therapy is developed by Shenzhen Second People's Hospital for the treatment of relapsed or refractory B-cell malignancies, including B-cell leukemia and B-cell lymphoma. The T cells are genetically engineered using lentiviral or retroviral vectors to express a CAR targeting the CD19 antigen, a protein widely expressed on the surface of B-lineage cells. The construct incorporates CD28 and CD3 zeta costimulatory domains to enhance T-cell activation, proliferation, and persistence. A distinguishing feature of this specific CAR-T product is the inclusion of a 'safety switch' designed to allow for the rapid elimination of the engineered cells in the event of severe adverse events, such as cytokine release syndrome (CRS) or neurotoxicity.

Other names

Anti-CD19-CAR transduced T cellsAnti-CD-19-CAR transduced T cellsAnti-CD 19-CAR transduced T cellsCD19 CAR-T cells with safety switchCD-19 CAR-T cells with safety switchCD 19 CAR-T cells with safety switchanti-CD19 CAR T cells-Shenzhen Second People's Hospital